The BRAF study enrolled 20 patients with tumoral CRC BRAF mutation (comprising 10 patients with MSI tumor and 10 patients with MSS tumor) and 10 patients with tumoral CRC BRAF wild type and MSS. This evidence concerns the gene BRAF and colorectal carcinoma.